You have read all your free articles, to continue reading subscribe to read the rest of this content.
Herantis Pharma has completed an upsized directed share issue and listing on the Swedish First North Growth Market
This dual listing will further enable the advance its two innovative programs: CDNF in Parkinson’s Disease and drug candidate, Lymfactin, in Lymphedema.
As part of the offering Herantis issued a total of 618,018 new shares at a price of €6.72 EUR / SEK 71 per share bringing the total number o
